Legend:
CC = Vancouver Convention Centre
F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
|
|
|
525 !
|
Wed, 8/1/2018,
10:30 AM -
12:20 PM
|
CC-West 209
|
|
Clinical Trial Design- 6 — Contributed Papers
|
|
Biopharmaceutical Section
|
|
Chair(s): Rachael Wen, Sanofi
|
|
10:35 AM
|
Asymptotic MinP Method for Responder Analysis
Ming Zhou, Bristol-Myers Squibb Company; Mark Donovan, Bristol-Myers Squibb
|
|
10:50 AM
|
Estimating Probability of Simultaneous Success with Multiple Endpoints Using Truncated Multi-Variate Correlated Normal Distribution
Tianshuang Wu, AbbVie; Yihua Gu, AbbVie; Ziqian Geng, AbbVie; Saurabh Mukhopadhyay, AbbVie
|
|
11:05 AM
|
Measuring the Individual Benefits of a Medical or Behavioral Treatment Using Generalized Linear Mixed-Effects Models
Francisco Diaz, The University of Kansas Medical Center
|
|
11:20 AM
|
Comparison of Support Vector Machine and Conformal Inference of in Regression Prediction
Kao-Tai Tsai, Celgene
|
|
11:35 AM
|
Adaptive Dose Finding in Oncology Phase I-II Studies with Consideration of Tolerability and Efficacy
Rachael Liu, Takeda Pharmaceuticals ; Ling Wang, Takeda; David Sinclair, Google; Jianchang Lin, Takeda Pharmaceuticals
|
|
11:50 AM
|
How the ICH E9 Addendum Influenced a Phase III Clinical Trial with a Radiographic Endpoint
Ruvie Martin, Novartis Pharmaceuticals
|
|
12:05 PM
|
Floor Discussion
|
